Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?
Authors
Keywords
-
Journal
Expert Review of Clinical Pharmacology
Volume -, Issue -, Pages -
Publisher
Informa UK Limited
Online
2023-11-03
DOI
10.1080/17512433.2023.2279193
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Estimating the value of sodium‐glucose cotransporter‐2 inhibitors within the context of contemporary guidelines and the totality of evidence
- (2023) Phil McEwan et al. DIABETES OBESITY & METABOLISM
- American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update
- (2023) Susan L. Samson et al. Endocrine Practice
- Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes
- (2023) Neha J. Pagidipati et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease
- (2023) Aliza Hussain et al. JACC-Heart Failure
- Real-World Evaluation of GLP-1 Receptor Agonist Therapy Persistence, Adherence and Therapeutic Inertia Among Obese Adults with Type 2 Diabetes
- (2023) Ana Palanca et al. Diabetes Therapy
- Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Patients With Heart Failure and Preserved Ejection Fraction—Living on the Edge
- (2023) Alexander T. Sandhu et al. JAMA Cardiology
- Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US
- (2023) Jacob B. Pierce et al. JAMA Cardiology
- Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes and Cardiovascular Disease
- (2023) Jing Luo et al. JAMA Network Open
- Overcoming Therapeutic Inertia as the Achilles’ Heel for Improving Suboptimal Diabetes Care: An Integrative Review
- (2023) Boon-How Chew et al. Endocrinology and Metabolism
- Underuse of glucose-lowering medications associated with cardiorenal protection in type 2 diabetes: from delayed initiation to untimely discontinuation
- (2023) André J. Scheen The Lancet Regional Health Europe
- Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021
- (2023) Mariam Elmegaard Malik et al. The Lancet Regional Health Europe
- Post‐initiation predictors of discontinuation of the sodium‐glucose cotransporter‐2 inhibitors: A comparative cohort study from the United Kingdom
- (2023) Wajd Alkabbani et al. DIABETES OBESITY & METABOLISM
- Socioeconomic aspects of incretin-based therapy
- (2023) Thomas Karagiannis et al. DIABETOLOGIA
- 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes
- (2023) Nikolaus Marx et al. EUROPEAN HEART JOURNAL
- The Impact of Glucagon-Like Peptide-1 Receptor Agonist on the Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis and Systematic Review
- (2023) Ali Rahman et al. Cardiology Research
- Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association
- (2022) Joshua J. Joseph et al. CIRCULATION
- Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes
- (2022) Alison K. Wright et al. DIABETES CARE
- Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs
- (2022) Dhruv Mahtta et al. DIABETES CARE
- Adherence and persistence rates of major antidiabetic medications: a review
- (2022) David Seung U. Lee et al. Diabetology & Metabolic Syndrome
- Use of Lipid-, Blood Pressure–, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
- (2022) Adam J. Nelson et al. JAMA Network Open
- The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
- (2022) Dario Giugliano et al. Cardiovascular Diabetology
- Sodium‐glucose co‐transporter‐2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice
- (2022) Kamlesh Khunti et al. DIABETES OBESITY & METABOLISM
- Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
- (2022) Suzanne V. Arnold et al. BMC Endocrine Disorders
- Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
- (2022) Melanie J. Davies et al. Cardiovascular Diabetology
- Glucose control independent mechanisms involved in the cardiovascular benefits of glucagon-like peptide-1 receptor agonists
- (2022) Qinchao Wu et al. BIOMEDICINE & PHARMACOTHERAPY
- Ethnic and socioeconomic disparities in initiation of second‐line antidiabetic treatment for people with type 2 diabetes in England: A cross‐sectional study
- (2022) Patrick Bidulka et al. DIABETES OBESITY & METABOLISM
- Sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real‐world clinical practice? A systematic review and meta‐analysis of observational studies
- (2022) William Hinton et al. DIABETES OBESITY & METABOLISM
- Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2022) Melanie J. Davies et al. DIABETOLOGIA
- Inadequate Use of Newer Treatments and Glycemic Control by Cardiovascular Risk and Sociodemographic Groups in US Adults with Diabetes in the NIH Precision Medicine Initiative All of Us Research Program
- (2022) Divya Devineni et al. CARDIOVASCULAR DRUGS AND THERAPY
- GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes
- (2022) Nikolaus Marx et al. CIRCULATION
- Early type 2 diabetes treatment intensification with glucagon‐like peptide‐1 receptor agonists in primary care: An Australian perspective on guidelines and the global evidence
- (2022) Roy Rasalam et al. DIABETES OBESITY & METABOLISM
- Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis
- (2022) Jedidiah I. Morton et al. DIABETOLOGIA
- " Type 2 Diabetes: Contemporary Challenges " Clinical Pharmacology of Antidiabetic Drugs: what can be expected of their use?
- (2022) André J. Scheen PRESSE MEDICALE
- Use of sodium–glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes
- (2022) Carl-Emil Lim et al. European Journal of Preventive Cardiology
- Instituting a Successful Discharge Plan for Patients With Type 2 Diabetes: Challenges and Solutions
- (2022) Andrew P. Demidowich et al. Diabetes Spectrum
- Gaps in Evidence‐Based Therapy Use in Insured Patients in the United States With Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease
- (2021) Adam J. Nelson et al. Journal of the American Heart Association
- Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye?
- (2021) Ele Ferrannini et al. DIABETES CARE
- Medication adherence to injectable glucagon‐like peptide‐1 (GLP‐1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: A meta‐analysis
- (2021) Erin R. Weeda et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis
- (2021) Chun-xing Li et al. PLoS One
- Effects of sodium‐glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta‐analysis of randomized controlled trials
- (2021) Caiyun Zheng et al. Cardiovascular Diabetology
- Contemporary National Patterns of Eligibility and Utilization of Novel Cardioprotective Anti‐hyperglycemic agents in Type 2 Diabetes
- (2021) Arash A Nargesi et al. Journal of the American Heart Association
- Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community
- (2021) Adam J. Nelson et al. CIRCULATION
- Second-Line Therapy for Type 2 Diabetes Management: The Treatment/Benefit Paradox of Cardiovascular and Kidney Comorbidities
- (2021) Rozalina G. McCoy et al. DIABETES CARE
- Individual, healthcare professional and system‐level barriers and facilitators to initiation and adherence to injectable therapies for type 2 diabetes: A systematic review and meta‐ethnography
- (2021) Jo Byrne et al. DIABETIC MEDICINE
- Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care
- (2021) Stephan Jacob et al. DRUGS
- SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
- (2021) Emily Brown et al. LANCET
- Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
- (2021) Gloria M. Gager et al. Frontiers in Cardiovascular Medicine
- SGLT-2 inhibitors in heart failure: Time for broader eligibility and earlier initiation
- (2021) Enrico G. Ferro et al. CLEVELAND CLINIC JOURNAL OF MEDICINE
- The rise of SGLT2 inhibitors: the time is now for cardiovascular specialists to lead the charge
- (2021) Nicholas B. Norgard et al. POSTGRADUATE MEDICINE
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
- (2021) Naveed Sattar et al. Lancet Diabetes & Endocrinology
- Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013–2018
- (2020) Chintan V. Dave et al. DIABETES CARE
- Poor adherence and persistence to sodium glucose co-transporter 2 inhibitors in real world settings: evidence from a systematic review and meta-analysis
- (2020) Richard Ofori-Asenso et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials
- (2020) Olivia R Ghosh-Swaby et al. Lancet Diabetes & Endocrinology
- Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits
- (2020) Yumin Gao et al. AMERICAN HEART JOURNAL
- Assessing the cost‐effectiveness of SGLT2i in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real‐world evidence
- (2020) Phil McEwan et al. DIABETES OBESITY & METABOLISM
- 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
- (2020) Sandeep R. Das et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
- (2020) Martin R. Cowie et al. Nature Reviews Cardiology
- Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease
- (2020) Michael C. Honigberg et al. JAMA Cardiology
- Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
- (2020) Guntram Schernthaner et al. Cardiovascular Diabetology
- Guideline recommendations and the positioning of newer drugs in type 2 diabetes care
- (2020) Nikolaus Marx et al. Lancet Diabetes & Endocrinology
- Series: Implications of the recent CVOTs in type 2 diabetes
- (2019) André J. Scheen DIABETES RESEARCH AND CLINICAL PRACTICE
- The use of GLP‐1 receptor agonists in hospitalised patients: an untapped potential
- (2019) O.G. Mustafa et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- An update on the safety of SGLT2 inhibitors
- (2019) André J Scheen Expert Opinion On Drug Safety
- Cardiovascular and renal protection with sodium-glucose cotransporter type 2 inhibitors: new paradigm in type 2 diabetes management…and potentially beyond
- (2019) André J. Scheen Annals of Translational Medicine
- Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review
- (2019) Dongzhe Hong et al. PHARMACOECONOMICS
- Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control
- (2018) Silvio E. Inzucchi et al. CIRCULATION
- Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes
- (2017) Mirko Sikirica et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- SGLT2 Inhibitors: Benefit/Risk Balance
- (2016) André J. Scheen Current Diabetes Reports
- Potential side effects to GLP-1 agonists: understanding their safety and tolerability
- (2014) Agostino Consoli et al. Expert Opinion On Drug Safety
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now